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Summary The ability of a series of polysulphonated naphthylureas structurally related to suramin to inhibit
basic fibroblast growth factor (bFGF) or serum-stimulated growth of endothelial cells [either large vessel,
human umbilical vein endothelial cells (HUVEC) or microvascular, bovine adrenal capillary endothelial
(BACE) cells] and angiogenesis in vivo has been examined. The polyanions encompassed two main structural
variations, namely the number of aromatic amide groups intervening between two terminal naphthyl rings
and/or variation in the substitution pattern of the naphthyl rings. The polyanions were either inactive (group
I) or inhibited (group II) bFGF-stimulated uptake of [3H]methylthymidine by BACE cells. Group I com-
pounds shared a common structural feature in that they were simple binaphthyl-substituted ureas. In contrast,
group II compounds all had an extended multiple ring structure with at least two aromatic groups intervening
between the two terminal naphthyl rings. Compounds with either two or four intervening groups were
equipotent in blocking bFGF in vitro. However, compounds with two bridging aromatic groups were 5- to
10-fold less toxic than suramin in mice, suggesting a potential for an improved therapeutic ratio. The ability of
the polyanions to block bFGF-driven endothelial cell proliferation in vitro correlated with antiangiogenic
activity in vivo as shown by use of the rat sponge angiogenesis model. These observations could substantially
widen the anti-tumour therapeutic opportunities for this class of compound.
Suramin is a polysulphonated naphthylurea that has been
employed in the treatment of onchocerciasis and trypano-
somiasis for over 50 years. In the light of selective toxicity of
suramin for the adrenal cortex, it was examined as a poten-
tially novel anti-cancer agent in the treatment of metastatic
adrenocortical carcinoma and shown to have some activity
(La Rocca et al., 1990a, b). Suramin has also been employed
in the treatment of cancers that are unresponsive to conven-
tial chemotherapy, including prostate carcinomas (Myers et
al., 1990) and lymphomas (La Rocca et al., 1990c). Suramin
administered i.p. has in addition been shown to inhibit
growth of human osteosarcoma xenografts in Balb/cA-nu/nu
mice for periods of up to 9 weeks (Walz et al., 1991).
In vitro, suramin has been shown to block the growth-
stimulating activity of several growth factors, including
platelet-derived growth factor (PDGF) (Williams et al., 1984;
Hosang, 1985; Coffey et al., 1987), epidermal growth factor
(EGF) (Coffey et al., 1987; Kopp & Pfeiffer, 1990), transfor-
ming growth factor P (TGF-P) (Coffey et al., 1987; Kopp &
Pfeiffer, 1990), insulin-like growth factor 1 (IGF-1) (Pollack
& Richard, 1990) and most recently growth factors for
endothelial cells, including members of the fibroblast growth
factor (FGF) family (Coffey et al., 1987; Moscatalli &
Quarto, 1989; Wellstein et al., 1991) and vascular endothelial
growth factor (Olander et al., 1991). A recent, detailed study
of the interaction of suramin with growth factors has shown
that it blocks acidic FGF (aFGF) activity by aggregation of
the growth factor into suramin aFGF multimers, with an
aFGF to suramin ratio of 2:1 (Middaugh et al., 1992).
Suramin similarly aggregated bFGF and PDGF, but not
IGF-1. However, although suramin was unable to aggregate
IGF-1, it induced a conformational change in the molecule as
judged from circular dichroic spectroscopy. A conforma-
tional change could interfere with receptor binding. Never-
theless, further studies are required to elucidate fully the
mechanism of the anti-growth factor activity of suramin.
While the aforementioned studies have shown that suramin
is able to block the binding of growth factors to their recep-
tors in intact cells by binding either to the growth factor
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itself, e.g. FGF and PDGF (Hosang, 1985; Middaugh et al.,
1992), or possibly to the growth factor receptor, it has other
diverse activities that probably contribute to its anti-
proliferative and antimetastatic activities. These include, in
the context of antiproliferation, inhibition of key enzymes
involved in the intracellular transduction of mitogenic sig-
nals, e.g. phosphoinositol and diacylglycerol kinases (Kopp
& Pfeiffer, 1990), protein kinase C (Hensey et al., 1989), DNA
polymerases (Spigelman et al., 1987) and topoisomerase II
(Bojanowski et al., 1992). Suramin has also been shown to
disrupt the coupling of G-proteins to receptors (Butler et al.,
1988). In contrast, the studies of Nakajima et al. (1991) have
suggested that the antimetastatic effect of suramin may be
due to its anti-invasive as well as its antiproliferative
activities. Thus, suramin was without effect on the growth
rate of B16 melanoma cells but strongly inbibited B16
melanoma heparinase and invasion by these cells of an extra-
cellular matrix.
A limitation on the clinical use of suramin is the narrow
margin between the dose required to achieve anti-tumour
activity and that leading to the onset of prohibitive toxic
side-effects. Suramin toxicity has been reviewed by La Rocca
et al. (1990a). It is clear from studies so far that a suramin
derivative with similar anti-tumour activity to suramin itself
but substantially lower toxicity would be of considerable
potential value. With the exception of Baghdiguian et al.
(1990), who looked at the ability of five suramin-like com-
pounds to induce enterocyte-like differentiation of human
colon carcinoma cells, little has been published to date con-
cerning structure-activity relationships of the anti-tumour
activity of suramin. It has been known for many years that a
small variation in the structure of the suramin molecule leads
to a rapid fall in trypanocidal activity. For example, CPD16
(see Figure 2, below), in which the two methyl groups of
suramin are replaced by hydrogen, has only about 5% of the
trypanocidal activity of suramin (Fourneau et al., 1924). In
contrast, inhibition of HIV-1 reverse transcriptase is much
less sensitive to structural modification and the struc-
ture-activity relationships are completely different from
those of its trypanocidal or antifilarial activity (Jentsch et al.,
1987).
Microvascular endothelial proliferation is postulated to be
a key event in the complex process of tumour angiogenesis
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(Denekamp & Hobson, 1982; D'Amore & Thompson, 1987).
Other steps include endothelial cell migration, tube formation
and anastomoses (for more detail see D'Amore & Thomp-
son, 1987; Bicknell & Harris, 1992). In view of the recent
report that suramin can exert an antiangiogenic effect
(Pesenti et al., 1992), it was of interest to us to examine some
structurally related polyanions for their ability to inhibit
bFGF-stimulated capillary endothelial cell proliferation and
subsequently angiogenesis in vivo. Sixteen polysulphonated
naphthylureas were examined, and we have identified struc-
tural features of the suramin molecule that endow growth
factor-blocking activity and, further, show that some of the
polyanions have at least equivalent antiangiogenic activity to
suramin but are 5- to 10-fold less toxic to mice.
1 ngml-I bFGF in fresh Dulbecco's modified Eagle medium
(DMEM)/serum. Cells were subsequently treated in the same
way every 2 days, at which point replicates were removed
with trypsin and counted in a Coulter counter to enable
construction of growth curves.
Determination of high-affinity binding of ['251]bFGF High-
affinity binding of bFGF to confluent, quiescent BACE cell
monolayers that had been treated as those for [3H]methyl-
thymidine uptake was determined as described for bFGF
binding to fibroblasts by Moscatelli and Quarto (1989).
Carrier-free bFGF was iodinated with 'Enzymo-beads' ac-
cording to the manufacturer's (Bio-Rad) instructions. Total
binding was determined with 1 ngml' labelled bFGF in
100ngml-' unlabelled bFGF. Specific binding was deter-
mined by competition with a 10-fold excess of unlabelled
bFGF (i.e. 1 mg ml-').
Materials and methods
Materials
Bovine adrenal capillary endothelial (BACE) cells were
isolated by clonal selection from cultures of collagenase-
digested adrenals as previously described (Fawcett et al.,
1991; McCarthy & Bicknell, 1992). Human umbilical vein
endothelial cells (HUVECs) were isolated by collagenase
digest of perfused umbilical veins (Jaffe et al., 1973) and used
up to the fourth passage. Suramin was a gift from Bayer
(Leverkusen, Germany). Suramin derivatives synthesised as
previously described (Balaban & King, 1927) were obtained
from T.J. Scott-Finnigan (Division of Parasitology, National
Institute for Medical Research, Mill Hill, London, UK), who
also supplied information on the maximum tolerated dose
(MTD) in mice following i.p. injection. All polyanions were
without anti-parasitic activity against Litomosoides carinii in
vivo (data supplied by T.J. Scott-Finnigan and J. Williams).
Stock solutions of suramin and suramin derivatives were
dissolved in water, sterile filtered and stored at -80°C. The
purity of the derivatives was examined by TLC on Merck
Kieselgel 60 F254 0.2 mm precoated plates run in chloro-
form-methanol-water (10:10:3). All compounds resolved to
a single spot except CPD9 and CPD14, which contained a
minor contaminant but were nevertheless >95% pure. The
structures of CPD12 and CPD14 were confirmed by mass
spectrometry. Human recombinant bFGF was from either
British Bio-Technology (Oxford, UK) or Genzyme (West
Malling, Kent, UK). Pentosan polysulphate was from Sigma.
Bandieraea simplicifolia lectin 1, isolectin B4, was from Vector
Labs (Peterborough, UK). [3H]methylthymidine (2 Ci mmol ')
and '33Xe-saline were from Amersham (Amersham, UK).
Polyether foam sheet was from R.E. Carpenter (Suffolk,
UK). Polythene tubings were from Portex, UK. Fetal calf
serum (FCS) was from J. Bio (Les Ulis, France). All other
tissue culture media were prepared at the ICRF Clare Hall
Laboratories, South Mimms, UK.
Methods
[3H]methylthymidine uptake assay Cells were seeded into 96
well gelatin-coated tissue culture plates in the presence of the
specified concentration of FCS and left to quiesce for the
number of days indicated for each experiment described in
the Results section. Cells were then fed with fresh 5% or
10% FCS with or without I ngml1' of bFGF and 0.5 tCi of
[3H]methylthymidine per well and with or without inhibitor.
Cells were harvested 48 h later with an automated Pharmacia
Wallac 96 well harvester directly onto filter mats. Filter mats
were counted in a Pharmacia flat-bed betaplate scintillation
counter.
Growth curves Growth curves were determined by seeding
cells into gelatin coated six well plates in a percentage of
FCS specified in each experiment and allowed to quiesce for
the indicated number of days. When quiescent (now labelled
day 0), the cells were treated with inhibitor, with or without
Rat sponge angiogenesis assays Sterile circular polyether
sponge discs (5 mm thick, 1.2 cm diameter) with central can-
nulae (1.3 cm long, 1.4 mm internal diameter) were implanted
subcutaneously in male Wistar rats (180-200 g) after induc-
tion of neuroleptanalgesia by Hypnorm (0.315 mgml1 fen-
tanyl citrate and 10mg ml-' fluanisone; 0.5 ml kg-', i.m.).
Four sponges were used in each experimental group. bFGF
(100 ng) either with or without polyanion (in the latter case
premixed) was injected daily into the sponge in 25 .ld of
phosphate-buffered saline. The neovascular response was
assessed as a function of blood flow through the implants by
direct injection of "'Xe-saline into the sponge and its
clearance monitored over a 6min period to determine the
half-life for clearance from the sponge (Andrade et al., 1987;
Fan et al., 1992). Sponge sections (10jLm) were stained with
haematoxylin and eosin or the endothelial cell marker Ban-
dieraea simplicifolia lectin 1, isolectin B4 (Laitinen, 1987), for
the assessment of cellularity and vascularity respectively.
Effects on tumour growth and weight loss Eight- to 12-week-
old category IV female C3H/He mice bred at the MRC RBU
were used for experiments. KHT tumours were maintained
by sequential passage of tumours in vivo. Subcutaneous
tumours were derived by injection of 2 x 105 viable cells
(obtained by trypsin/DNAse digestion of a maintenance
tumour) into the mid-dorsal pelvic region of the back.
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Figure 1 Effect of suramin and related polyanions (tested at a
concentration of 1 mM) on [3H]methylthymidine uptake by quies-
cent BACE cells in the presence and abscence of 1 ngml-'
bFGF. Conditions: BACE cells were seeded into 96 well plates at
1,000 cells per well in 10% FCS/DMEM and left for 12-14 days
to quiesce. They were then treated with polyanion, with or with-
out 1 ng ml-' bFGF and 0.5fiCi per well of [3H]methylthymidine
in fresh 2% FCS/DMEM. Cells were harvested 48 h later
(mean ± s.e.m., n = 5). ( _ ) + I ng ml bFGF; ( ) no
bFGF. All polyanions were examined at least twice.892 P.S. BRADDOCK et al.
Equimolar doses of the antiangiogenic drugs were admini-
stered by the i.p. route on days 1, 5, 9, 13 and 17 following
implantation, which is similar to the protocol followed by
Walz et al. (1991). Tumours were measured as soon as they
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Figure 2 Chemical structure of suramin and related polyanions examined in this study.POLYANION ANTAGONISM OF bFGF 893
Results
Effect ofsuramin and structurally relatedpolyanions on
capillary (BACE) cell [3H]methylthymidine uptake
An evaluation procedure was developed to determine the
ability of suramin and structurally related polyanions to
inhibit bFGF-stimulated capillary (BACE) cell [3H]methyl-
thymidine uptake, and Figure 1 shows a representative set of
results. All polyanions were either without activity (group I)
or they inhibited bFGF-stimulated BACE cell [3H]methyl-
thymidine uptake (group II). Figure 2 groups the polyanions
by activity and chemical structure.
We chose polyanions showing the most potent inhibition
of BACE cell [3H]methylthymidine uptake and lowest toxicity
in mice (see Table I) for further study of their effects on
capillary endothelial cell [3H]methylthymidine uptake.
Figure 3 illustratres dose-response curves for the inhibi-
tion of BACE cell [3H]methylthymidine uptake by suramin
and four chosen inhibitory polyanions, namely CPDs 8, 11,
12 and 14. It is clear from this figure that all four derivatives
Table I Mouse toxicity data for suramin analogues that inhibit
bFGF-driven BACE cell proliferation
Maximum tolerated dose
Suramin analogue mgkg-' pmolkg-'
Suramin 100 70
CPD7 1,000 1,506
CPD8 250 219
CPD9 250 575
CPDIO 250 225
CPDll 250 225
CPD12 500 647
CPD13 100 99
CPD14 250 277
CPD15 100 87
CPD16 100 78
Mouse toxicity was examined by giving a fixed daily i.p. dose to
mice on each of 4 consecutive days. Suramin or derivatives were
given at either 2, 5, 10 or 20 mg per 20 g of mouse body weight.
Eight mice were examined per group. The maximum tolerated dose
was taken as that administered that gave rise to no mouse deaths
withn the 4 day experiment. Experiments were performed once.
Controls received saline vehicle which gave rise to no mouse deaths.
-20-
00
?20-
.9 40-
c 60-
80
0.1 1 10 100 1,000
Drug concentration (>M)
Figure 3 Dose-response curves for the inhibition of bFGF-
stimulated quiescent BACE cell [3H]methylthymidine uptake.
Effect of suramin (0) and the related polyanions CPD8 (@),
CPD11 (0), CPD12 (-) and CPD14 (A). Conditions: BACE
cells were seeded into gelatin-coated 96 well plates at 6,000 cells
per well in 0.5% FCS/DMEM and left for 12 days to quiesce.
Cells were then treated with 1 ng ml-' bFGF in 0.5% FCS/
DMEM, 0.5jtCi of [3HJmethylthymidine per well and the appro-
priate concentration of polyanion. Cells were harvested 48 h later
(mean ± s.e.m., n = 5). Dose-response curves were determined
three times. The mean and s.d. of the IC50 value for selected
analogues are given in Table II.
are active and that CPD8, CPDl1 and CPD14 appear to be
an order of magnitude more potent than suramin in the
inhibition ofbFGF-stimulated BACE cell [3H]methylthymidine
uptake. IC50 values were determined from the dose-response
curves and are given in Table II. CPD12 and CPD14 had the
most favourable ratio of IC50 to maximum tolerated dose
(MTD) and were chosen for further study.
Inhibition ofBACE cellgrowth by suramin and
suramin-relatedpolyanions
Figure 4 shows the effect of two polyanions, CPD6 and
CPD14, and suramin on BACE cell growth. Drugs were
again tested at a concentration of 100jaM. CPD14 was
chosen as a typical derivative exhibiting strong inhibition of
BACE cell [3H]methylthymidine uptake (i.e. a group II
member) (Figure 3) and CPD6 as a group I member (Figure
2). In accord with the [3H]methylthymidine uptake data,
CPD6 was without effect on bFGF-stimulated growth,
whereas CPD 11 was equipotent to suramin in blocking
bFGF-stimulated growth. In the absence of bFGF neither
suramin nor CPD1 1 showed toxicity when cells were treated
with 100iLM drug for at least 9 days of treatment (data not
shown).
Table III shows that the activity-blocking polyanion
CPD14 reduces the specific binding of bFGF to BACE cells,
as has been reported for suramin and bFGF binding to 3T3
fibroblasts (Moscatelli & Quarto, 1989). In contrast, CPD7,
which had shown no antagonism of the growth factor
Table II IC50 values ofsulphonated naphthylureas for the inhibition
of bFGF-stimulated BACE cell [3H]methylthymidine uptake
IC50
Suramin 98 23
CPD8 39.3 30
CPD9 276 201
CPD1O 16.8 11.4
CPDll 4.1±2.8
CPD12 164±36
CPD14 6.2±0.2
IC_O values (expressed as JM) were obtained from inhibition
profiles, examples of which are shown in Figure 3. Mean s.d.
(n = 3).
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Figure 4 Growth curves for BACE cells treated with suramin or
related polyanions in the presence of I ngml-I bFGF. Control
(0), suramin (0), CPD6 (O) and CPD14 (0). Conditions:
BACE cells were seeded at 10,000 cells per well into gelatin-
coated six well plates in 5% FCS/DMEM and left for 7 days to
quiesce. Cells were then treated with 100 IM polyanion and
1 ngml-' bFGF in 5% FCS/DMEM. Cells were treated on days
at which duplicates were counted. Points are the average of two
wells. The experiment was repeated with similar results.894 P.S. BRADDOCK et al.
Table III Effect of suramin, CPD7 and CPD14 on the specific
binding of [1251]bFGF to BACE cells
Specific binding (counts per 10 min)
1 2 3
Control 4,642 43,761 3,428
Suramin -775 1,376 928
CPD7 ND 44,621 2,785
CPD14 918 1,155 500
The results are given for three separate experiments. Specific
binding was that inhibited by a 10-fold excess of unlabelled bFGF.
Polyanions were added at a concentration of 1 mgml-'. CPD7 is a
representative group I (inactive in blocking bFGF-stimulated
[3H]methylthymidine uptake) polyanion with a structure closest to
that of CPD14. The difference in the actual counts between
experiments is due to differences in the specific activity of the
radioiodinated bFGF.
activity of bFGF, also had no effect on the specific binding
of bFGF to BACE cells.
Comparison ofthe inhibition of[3H]methylthymidine uptake
in BACE cells and HUVECs by suramin, CPDJJ andpentosan
polysulphate
It has been reported that pentosan polysulphate (PPS)
inhibits K-FGF (FGF-4)-stimulated endothelial proliferation
(Wellstein et al., 1991). Figure 5 compares the inhibition of
[3H]methylthymidine uptake by (a) suramin, (b) CPD1 1 and
(c) PPS in both HUVECs and BACE cells. Inhibition of
[3H]methylthymidine uptake by capillary cells occurred at a
lower concentration of drug than was required to block
bFGF-stimulated uptake by HUVECs. Indeed, with
HUVECs, significant inhibition was not observed with less
than millimolar concentrations of suramin or CPD11,
whereas suramin and CPDl1 gave nearly 50% inhibition of
BACE cell [3H]methylthymidine uptake at a concentration of
1 JiM. We conclude that microvascular endothelium appears
to be more sensitive to inhibition by these compounds than is
large-vessel endothelium. This could reflect stronger growth-
promoting activity of bFGF on BACE cells as opposed to
HUVECs (R. Bicknell, unpublished observations).
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Figure 5 Comparison of the inhibitory activity of suramin (a),
CPD 1 (b) and pentosan polysulphate (c) on microvascular
(BACE) (0) and large-vessel (HUVEC) (0) endothelium. The
experiment was repeated with similar results.
Effect ofsuramin and derivatives on bFGF-stimulated
angiogenesis in vivo
The study of Pesenti et al. (1992) has shown that i.v. suramin
is able to block bFGF-induced vascularisation of a gelatin
sponge implanted subcutaneously in rats. We have employed
a similar model to examine the antiangiogenic activity of the
related polyanions. A polyether sponge was employed rather
than the gelatin sponge of Pesenti et al. (1992), which unlike
the gelatin sponge spontaneously vascularises slowly as a
result of an inflammatory response.
In all experiments the primary angiogenic stimulus was
100 ng of bFGF in 25 lI of PBS injected daily directly into
the sponge. Polyanion antagonism of bFGF-induced angio-
genesis was assessed in two ways. The polyanion was either
mixed with the bFGF immediately prior to daily injection
into the sponge, or alternatively given as a single dose (in
400yl of PBS) into the tail vein on the day of sponge
implantation. Figure 6 shows that suramin was able to block
bFGF-driven sponge angiogenesis when administered daily
into the sponge at doses of 3 and 10 mg, but not when only
1 mg was given. Figure 6b shows that a single dose of 40 mg
of suramin i.v. substantially reduces bFGF-driven sponge
angiogenesis for up to 14 days.
The experiments were repeated with three of the
polyanions, namely CPD14, which effectively blocks bFGF
activity in vitro, and CPD1 and CPD7, which were unable to
antagonise bFGF in vitro. Figure 6c and d shows that
CPD14 is as effective as suramin at blocking bFGF-driven
angiogenesis both when administered directly into the sponge
and when given as a single dose i.v. on the day of sponge
implantation. Neither CPDI (Figure 6e and f) or CPD7 (data
not shown) was able to prevent bFGF-stimulated
angiogenesis.
Histological examination ofthe sponge implants
Figure 7 shows some histological sections of sponge implants
after staining with haematoxylin and eosin. Administration
of active polyanions either directly into the sponge or i.v.
retarded invasion of the sponge by both fibroblasts and
vasculature. Histological examination after staining with
Bandieraea simplicifolia lectin to visualise the vasculature
revealed no remarkable differences in the tissue or vessels in
sponges from different experimental groups. The only
difference was simply one of extent of invasion into the
sponge. Some inflammatory cells were present in all sponges,
but again there were no significant differences between
sponges.
Toxicity ofCPD14 compared with suramin
Figure 8 gives the percentage change in body weight of mice
implanted with KHT tumours comprising three groups, con-
trols and those receiving either suramin or CPD14. Mice
receiving suramin showed a marked loss in body weight not
seen in either controls or in those receiving equimolar quan-
tities of CPD14. In these same experiments a significant
anti-tumour effect was seen with both suramin and CPD14.POLYANION ANTAGONISM OF bFGF 895
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Figure 6 Effect of (a and b) suramin, (c and d) CPD14 and (e and f) CPDl on the rate of "'Xe clearance from a polyester sponge
implanted subcutaneously in the rat. bFGF (100 ng) was injected daily into the sponge. Control = a sponge alone that received no
bFGF. Drugs were administered either directly into the sponge daily (a, c and e) or given as a single dose on day 1 into the tail
vein (b, d and f). The experiments with suramin and CPD14 were carried out three times. Where statistically significant differences
between experimental groups are indicated in the figures ('P<0.05, "P<0.01), this was found to be the case in each of the three
experiments. As CPDI was without effect on the rate of "'Xe clearance from the sponges, this experiment was not
repeated.
KHT tumours in mice receiving no treatment with anti-
angiogenic drug took 14.9 ± 0.3 days from the time of im-
plant to reach a volume of 200 mm3. In comparison, this
time is increased to 19.2 ± 0.7 and 19.9 ± 0.5 days for
suramin and CPD14 respectively. Normally tumour-bearing
mice were sacrificed when tumours reached 500 mm3 or when
there were clinical signs of severe drug toxicity. The latter
were only apparent in mice treated with suramin. By day 16,
those mice receiving suramin showed poor coat condition,
lack of alertness in the eyes, oedema around the feet and the
base of the ears, some dermatitis/urticaria, bradypnoea and
slight photophobia. Organ histology of suramin-treated mice
showed in the kidney minor droplet degeneration of tubules,
and in the liver a non-degenerative droplet change. No other
organs showed gross histological abnormalities, although it
should be noted that on sacrifice the bones of the suramin-
treated mice were extremely brittle. There were no com-
parable clinical signs of toxicity in the CPD14-treated mice,
except for the weight loss on the day of sacrifice. No
significant difference in weight was observed in the rats em-
ployed in the sponge angiogenesis assay between either con-
trols or those receiving either suramin (3 mg per day into the
sponge or 40 mg single dose i.v.) or any of the polyanions
examined.
Discussion
The studies described here have shown that several polysul-
phonated naphthylureas with structures related to suramin,
but some of which are considerably smaller than the suramin
molecule itself, effectively block bFGF-stimulated BACE cell
growth and angiogenesis in the rat sponge model. The ana-
logues fall into two activity groups. Group I compounds are
inactive and group II compounds are inhibitory for BACE
cells (Figure 2). All group II derivatives have either two or
four bridging amide aromatic rings. It appears that the
extended ring structure is essential for inhibitory activity.
Some of these compounds are at least as active as, if not 5-
to 10-fold more active than, suramin (see Figure 3, CPD8
and CPD1 1) but are nevertheless substantially less toxic than
suramin in vivo (Table II). Indeed, some derivatives, e.g.
CPD9, CPD12 and CPD14, are 5- to 10-fold less toxic than
suramin in vivo. Figure 4 compares suramin with two other
analogues, CPD6 and CPD14. Suramin and CPD14 potently
blocked bFGF-stimulated growth, while CPD6, consistent
with its simple naphthyl-substituted urea structure (group I)
was inactive. Thus, it appears that the analogues that inhibit
['H]methylthymidine uptake by BACE cells also inhibit cell
growth. Further experiments supported a correlation between
the ability of a polyanion to block bFGF-driven
['H]methylthymidine uptake, BACE cell growth and
angiogenesis in vivo.
Other polyanions have been used to inhibit cell growth
(including that of endothelial cells), e.g. pentosan polysul-
phate (PPS), which is a heparin analogue that has been
reported to inhibit K-FGF-stimulated growth of SW13
adrenocortical cells transfected with the K-FGF gene (Well-
stein et al., 1991). These authors showed that PPS exhibited
selective inhibition of K-FGF-induced proliferation by a fac-
tor of 2,000, compared with inhibition by suramin and dext-
ran sulphate of 3- and 5-fold respectively. Further, it was
shown that while PPS was able to block [3H]methylthymidine
uptake by HUVECs when stimulated by conditioned medium
from SW13 cells transfected with K-FGF, it did not block
that stimulated by exogenous bFGF.
Tumour angiogenesis is a process that involves the micro-
vasculature. In view of the differential response of large
vessel and microvascular endothelium to growth factors (see
McCarthy et al., 1991) it is of importance to study the
growth-inhibitory activity of potential antiangiogenic com-
pounds with microvascular (e.g. BACE cells) as opposed to896 P.S. BRADDOCK et al.
*: :.:
b d ii.:it0t:fiA,>S i.ji;;l.,;~~~~~~~~~~~~~~~~~~~~~~~~~;;.-"
. ............ rd
11iV R iS
P
i EqtlF ;Ji '*;;i'(M 4 2 # 0 W00gA,A1i2g00zX rt w , >1iWtGll?yJ~~~.%.Aw.
Y'A7
--d
1< t k 0 0lj jGEL~~~~~~~A
Figure 7 Histology of sponge implants. a, Day 8 control sponge. b, Day 8 after daily injection of bFGF 100 ng into the sponge. c,
Day 8 after daily injection of bFGF 100 ng and suramin 3 mg into the sponge. d, Day 8 after daily injection of bFGF 100 ng and
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Figure 8 Weight loss data for KHT tumour-bearing mice. Con-
trol (0), suramin treated (@) and CPD14 treated (0). Suramin
(60mg kg-' i.p.) and CPD14 (42mg kg-' i.p.) were given on
days 1, 5, 9, 13 and 17 after implant. The control group com-
prised 34 mice. The suramin and CPD14 groups contained eight
mice each. Mice received a subcutaneous implant of KHT
tumour cells on the back at day 0.
large-vessel (HUVEC) endothelium. Previous studies with
PPS only employed large-vessel endothelium, and so we com-
pared the inhibitory activity of suramin, CPDII and PPS on
bFGF-stimulated large-vessel (HUVEC) and capillary
(BACE) endothelium. It is clear that while suramin, CPDII
and PPS can block [3H]methylthymidine uptake by HUVECs
in response to 1 ng ml-' bFGF, significant inhibition is seen
only at millimolar concentrations of inhibitor. In contrast,
BACE cells were substantially more sensitive to inhibition by
all three inhibitors. Thus ICso values for suramin and CPD1 1
are in the region of 10 ylM, that is 10- to 100-fold lower than
for HUVECs. Figure 5c shows that PPS inhibits bFGF-
driven HUVEC and BACE cell [3H]methylthymidine uptake,
and that BACE cells are inhibited at lower concentrations
than are HUVECs. However, in contrast to studies on block-
ing of conditioned media from SW13 cells transfected with
K-FGF, we found that PPS was no more active in blocking
bFGF-driven [3H]methylthymidine uptake in either HUVEC
or BACE cells than was suramin or CPD 1. This may reflect
different interactions with members of the FGF family or a
difference in experimental conditions, e.g. bFGF concentra-
tions in our assays. Another study (Zugmaier et al., 1992)
has shown that PPS given by daily intraperitoneal injection is
able to block the growth of tumours in xenografted nude
mice in a dose-dependent fashion. However, PPS failed to
affect the growth of established tumours (i.e. where the
tumour burden exceeded 1Omm2).
CPD14 and CPD15 together with CPD7 form a structural
series the members of which differ only in the number of
intervening rings between the substituted naphthyl rings
(Figure 2). As such they clearly illustrate the absolute
requirement of the intervening rings for inhibitory activity.
Thus, CPD7 is inactive on BACE cells, whereas CPD14 and
CPD15 strongly inhibited both cell types. Interestingly, the
most favourable ratio of IC_0 to MTD was seen with com-
pounds that have two bridging rings, e.g. CPD12 and CPD14
(Table II). This is largely because these compounds have
essentially equipotent growth-inhibiting activity to com-
pounds with four bridging rings, but reduced toxicity. In
contrast to the clear requirement for bridging rings in the
structure, our studies have so far failed to reveal clear struc-
ture-activity relationships pertaining to the substitution pat-
tern of the naphthyl rings.
Hori et al. (1991) transfected the bFGF gene with an IgG
secretion signal added into non-tumorigenic A31 cells and
conferred tumorigenicity. Tumorigenicity was strongly
antagonised by i.v. administration of anti-bFGF monoclonal
antibodies, pointing to a potentially crucial role for bFGF in
tumour growth. Similar effects have recently been reported
with antibodies that block the activity of VEGF (Kim et al.,
1993). The strong interaction of suramin with heparin-
binding growth factors (Middaugh et al., 1992) suggests that
the analogues may also be effective against other heparin-
binding growth factors. It is notable that all of the best-
characterised angiogenic factors are also heparin binding (e.g.
aFGF, VEGF, placental growth factor, pleiotrophin). Never-
theless, the antiangiogenic activity of suramin-like molecules
is unlikely to be attributable solely to attenuation of the
interaction of bFGF with its receptor but also to arise from
its activities on cells' proliferative apparatus as outlined in
the introduction.
We conclude that polyanions of similar structure to the
suramin molecule are able to block bFGF-stimulated growth
of capillary endothelium in vitro and bFGF-driven
angiogenesis in vivo. These, together with their lower toxicity,
offer the opportunity of widening the suramin 'therapeutic
window'. CPD12 and CPD14 appear to offer particular pro-
mise and are being examined further.
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